Kaken Pharmaceutical Co., Ltd. (4521.T)
JPY 4192.0
(-2.58%)
JPY 4192.0
(-2.58%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 9.51 Billion JPY | 18.95% |
| 2022 | 7.99 Billion JPY | -53.13% |
| 2021 | 17.06 Billion JPY | -4.07% |
| 2020 | 17.78 Billion JPY | -32.91% |
| 2019 | 26.51 Billion JPY | 7.81% |
| 2018 | 24.59 Billion JPY | -10.56% |
| 2017 | 27.49 Billion JPY | -10.46% |
| 2016 | 30.7 Billion JPY | -12.63% |
| 2015 | 35.14 Billion JPY | 70.36% |
| 2014 | 20.63 Billion JPY | 29.98% |
| 2013 | 15.87 Billion JPY | 8.63% |
| 2012 | 14.61 Billion JPY | -23.46% |
| 2011 | 19.08 Billion JPY | 4.73% |
| 2010 | 18.22 Billion JPY | 17.27% |
| 2009 | 15.54 Billion JPY | 7.15% |
| 2008 | 14.5 Billion JPY | 4.47% |
| 2007 | 13.88 Billion JPY | 11.69% |
| 2006 | 12.43 Billion JPY | -2.06% |
| 2005 | 12.69 Billion JPY | 3.13% |
| 2004 | 12.3 Billion JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 2.75 Billion JPY | 174.91% |
| 2023 Q1 | 3.29 Billion JPY | 174.91% |
| 2023 FY | 9.51 Billion JPY | 18.95% |
| 2023 Q4 | 640 Million JPY | -80.96% |
| 2023 Q3 | 3.36 Billion JPY | 51.46% |
| 2023 Q2 | 2.21 Billion JPY | -32.61% |
| 2022 Q4 | -4.39 Billion JPY | -205.04% |
| 2022 Q1 | 4.05 Billion JPY | 27.75% |
| 2022 Q2 | 4.15 Billion JPY | 2.39% |
| 2022 Q3 | 4.18 Billion JPY | 0.77% |
| 2022 FY | 7.99 Billion JPY | -53.13% |
| 2021 Q1 | 4.42 Billion JPY | 55.72% |
| 2021 Q2 | 4.61 Billion JPY | 4.39% |
| 2021 Q3 | 4.85 Billion JPY | 5.16% |
| 2021 Q4 | 3.17 Billion JPY | -34.58% |
| 2021 FY | 17.06 Billion JPY | -4.07% |
| 2020 Q3 | 5.16 Billion JPY | 8.76% |
| 2020 FY | 17.78 Billion JPY | -32.91% |
| 2020 Q2 | 4.75 Billion JPY | -5.57% |
| 2020 Q1 | 5.03 Billion JPY | 23.31% |
| 2020 Q4 | 2.83 Billion JPY | -45.06% |
| 2019 Q4 | 4.08 Billion JPY | -53.04% |
| 2019 Q1 | 6.7 Billion JPY | 42.99% |
| 2019 Q2 | 7.03 Billion JPY | 4.98% |
| 2019 Q3 | 8.68 Billion JPY | 23.43% |
| 2019 FY | 26.51 Billion JPY | 7.81% |
| 2018 FY | 24.59 Billion JPY | -10.56% |
| 2018 Q4 | 4.68 Billion JPY | -37.87% |
| 2018 Q3 | 7.54 Billion JPY | 12.49% |
| 2018 Q1 | 5.64 Billion JPY | 49.0% |
| 2018 Q2 | 6.7 Billion JPY | 18.81% |
| 2017 Q2 | 7.68 Billion JPY | 0.48% |
| 2017 Q4 | 3.79 Billion JPY | -54.72% |
| 2017 Q3 | 8.37 Billion JPY | 8.91% |
| 2017 Q1 | 7.64 Billion JPY | 32.93% |
| 2017 FY | 27.49 Billion JPY | -10.46% |
| 2016 Q2 | 8.02 Billion JPY | -0.88% |
| 2016 Q3 | 8.83 Billion JPY | 10.02% |
| 2016 Q4 | 5.75 Billion JPY | -34.84% |
| 2016 FY | 30.7 Billion JPY | -12.63% |
| 2016 Q1 | 8.09 Billion JPY | 48.38% |
| 2015 Q3 | 11.24 Billion JPY | 22.12% |
| 2015 Q4 | 5.45 Billion JPY | -51.48% |
| 2015 FY | 35.14 Billion JPY | 70.36% |
| 2015 Q2 | 9.2 Billion JPY | -0.27% |
| 2015 Q1 | 9.23 Billion JPY | 129.7% |
| 2014 Q2 | 4.72 Billion JPY | 15.57% |
| 2014 Q3 | 7.8 Billion JPY | 65.33% |
| 2014 Q4 | 4.02 Billion JPY | -48.49% |
| 2014 FY | 20.63 Billion JPY | 29.98% |
| 2014 Q1 | 4.08 Billion JPY | 1.06% |
| 2013 Q4 | 4.04 Billion JPY | -9.62% |
| 2013 FY | 15.87 Billion JPY | 8.63% |
| 2013 Q1 | 3.47 Billion JPY | 40.47% |
| 2013 Q2 | 3.88 Billion JPY | 11.56% |
| 2013 Q3 | 4.47 Billion JPY | 15.26% |
| 2012 Q2 | 5.51 Billion JPY | 13.42% |
| 2012 FY | 14.61 Billion JPY | -23.46% |
| 2012 Q1 | 4.86 Billion JPY | 82.5% |
| 2012 Q3 | 1.76 Billion JPY | -67.92% |
| 2012 Q4 | 2.47 Billion JPY | 40.05% |
| 2011 Q4 | 2.66 Billion JPY | -54.6% |
| 2011 Q1 | 5.12 Billion JPY | 120.1% |
| 2011 Q2 | 5.43 Billion JPY | 6.11% |
| 2011 Q3 | 5.86 Billion JPY | 7.87% |
| 2011 FY | 19.08 Billion JPY | 4.73% |
| 2010 Q1 | 5.5 Billion JPY | 341.78% |
| 2010 Q4 | 2.32 Billion JPY | -61.23% |
| 2010 Q3 | 6 Billion JPY | 36.95% |
| 2010 Q2 | 4.38 Billion JPY | -20.42% |
| 2010 FY | 18.22 Billion JPY | 17.27% |
| 2009 Q2 | 4.29 Billion JPY | -1.06% |
| 2009 Q3 | 5.67 Billion JPY | 32.18% |
| 2009 Q4 | 1.24 Billion JPY | -78.01% |
| 2009 FY | 15.54 Billion JPY | 7.15% |
| 2009 Q1 | 4.33 Billion JPY | 448.29% |
| 2008 Q4 | 791 Million JPY | -84.57% |
| 2008 FY | 14.5 Billion JPY | 4.47% |
| 2008 Q3 | 5.12 Billion JPY | 21.09% |
| 2008 Q2 | 4.23 Billion JPY | 0.0% |
| 2007 FY | 13.88 Billion JPY | 11.69% |
| 2006 FY | 12.43 Billion JPY | -2.06% |
| 2005 FY | 12.69 Billion JPY | 3.13% |
| 2004 FY | 12.3 Billion JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | -86.055% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 95.556% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 102.686% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 94.452% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | 4965.711% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 69.69% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 82.188% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | -1228.631% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 27.751% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | -63.932% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | -384.369% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | 2025.709% |
| Tsumura & Co. | 20.01 Billion JPY | 52.478% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | -136.819% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | -88.9% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 46.096% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | -146.579% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 2.096% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | -58.207% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 408.964% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | -144.299% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | 1272.031% |
| MedRx Co., Ltd | -933 Million JPY | 1119.614% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | -84.647% |
| Solasia Pharma K.K. | -1.13 Billion JPY | 935.206% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 501.392% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | -46.354% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 49.629% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | 1463.994% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 50.789% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | -117.077% |